logo

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

European News

Daiichi Sankyo Master Prize: Award for the Best Graduate in Pharmaceutical Sciences at the University of Munich

Claudia Hildebrandt received the Daiichi Sankyo Master Prize 2014: Award for the best graduate of Pharmaceutical Sciences at the…

Plant Expansion: Daiichi Sankyo Inaugurates New Building for Pharmaceutical Development in Pfaffenhofen, Bavaria

  • Substantial investment of 13 Mio. Euros. Opening ceremony for new annexe after 2-year building period
  • Focus on Pharmaceutical Development: 100…

Global Survey of Cardiologists Highlights Complexity of Managing Non-Valvular Atrial Fibrillation and Reinforces Need for Individualized Approach to Patient Care

•    Findings show risk of bleeding, along with overall efficacy1, consistently ranked among top considerations for cardiologists when choosing a…

ESC Congress 2014: Make Your Heart Feel Good!

Visit Us at Booth J500!

World Hypertension Day 2014

Daiichi Sankyo “Makes Your Heart Feel Good!” with a pan-European charity initiative

Daiichi Sankyo Submits SAVAYSATM (edoxaban) Tablets New Drug Application to the U.S. FDA for Once-Daily Use for Stroke Risk Reduction in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial…

Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial…